Evaluating and improving next-generation cell-based immunotherapies

“Nothing in life is to be feared. It is only to be understood.”
- Marie Curie

Our aim is to provide cancer patients promising and pioneering treatment options by e.g., understanding the implication of inter- and intra-tumoral heterogeneity on success and failure of CAR therapy, which will contribute to the generation and improvement of next-generation immunotherapeutic products. Tailored genome editing combined with advanced stem cell applications will be evaluated and further developed in translatable preclinical settings to provide cell drugs that improve the quality of life of cancer patients - including their families.

Our work focuses on projects further developing novel cellular products from preclinical settings up to tech transfer for clinical manufacture which will directly lead to clinical application. We are driven to better characterize the crosstalk between engineered immune cells and tumor cells to understand cell interaction and its consequences. Our goal is to genetically engineer the next generation of cell products to prevent adverse events or relapses.